Check for updates

Non-covalent albumin-binding ligands for extending the circulating half-life of small biotherapeutics

Alessandro Zorzi, [iD] [a] Sara Linciano [iD] [b] and Alessandro Angelini [iD] *[bc]

Peptides and small protein scaffolds are gaining increasing interest as therapeutics. Similarly to full-length antibodies, they can bind a target with a high binding affinity and specificity while remaining small enough to diffuse into tissues. However, despite their numerous advantages, small biotherapeutics often suffer from a relatively short circulating half-life, thus requiring frequent applications that ultimately restrict their ease of use and user compliance. To overcome this limitation, a large variety of half-life extension strategies have been developed in the last decades. Linkage to ligands that non-covalently bind to albumin, the most abundant serum protein with a circulating half-life of ~19 days in humans, represents one of the most successful approaches for the generation of long-lasting biotherapeutics with improved pharmacokinetic properties and superior efficacy in the clinic.

1. Introduction

Peptides and small protein scaffolds have numerous potential benefits as biotherapeutics, including a high binding affinity, exquisite target specificity, low toxicity, and a relatively small size (<50 kDa) that enables them to diffuse into otherwise inaccessible spaces.[1–3] However, their direct application as drugs is often hampered by their rapid renal clearance that results in a short systemic half-life. Though there are some peptide drugs that do not need half-life extenders as they exert their desired pharmacological effect at the administration site (*e.g.* toxin-derived peptide drugs),[4] most peptides that have the potential to function as critical therapeutics are not available in the body long enough to be effective.[1–3] Thus, maintaining effective concentrations requires high dosages and frequent injections, affecting patient compliance.[5] In the last decades, a diverse set of strategies has been developed to prolong the half-lives of peptides and small proteins from minutes to several hours or even days. These approaches include conjugation to synthetic and natural polymers and direct linkage to genetically encoded, unstructured polypeptides and long-lived serum proteins.[5,6] Additionally, non-covalent binding to these long-lived endogenous proteins, such as serum albumin,[7–9] immunoglobulin (IgG),[10–16] neonatal Fc receptor (FcRn),[17–19] transthyretin,[20] transferrin and its receptor,[21–23] can enhance the pharmacokinetic properties of small biotherapeutics. In this approach, peptides and small proteins are directly connected to high-affinity binding moieties that non-covalently tether them to the serum proteins after injection, thus impairing their renal filtration. The affinity of the reversible ligands determines the percentage of free and bound bioactive molecule and balances the fraction available at the target site, which is irrelevant if the target is in the plasma where it can be acted upon by free or bound therapeutic. While most of these strategies have been thoroughly described elsewhere,[5,6] this review focuses exclusively on ligands that bind non-covalently to serum albumin. The intrinsic capability of albumin to act as a non-covalent "taxi" for a plethora of exogenous and endogenous molecules has enabled the development of small biotherapeutics with an extended half-life and superior efficacy in the clinic.[8,9]

2. Albumin as carrier

Albumin is the most abundant protein in plasma, with an average plasma concentration of ~40 g L^{-1} (600 μM), and it possesses remarkable solubility and stability.[8,24] It is a non-glycosylated, single-chain polypeptide comprising 585 amino acids in its mature form for a molecular weight of 66.5 kDa. The amino acid composition is characterized by a high percentage of ionic amino acids, with 83 and 98 positively and negatively charged residues, respectively.[24] The resulting negative net charge highly increases the solubility of albumin in aqueous solution. The protein also contains 17 disulfide bridges that contribute to its stability and a single odd cysteine

[a] Institute of Chemical Sciences and Engineering, School of Basic Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne CH-1015, Switzerland

[b] Department of Molecular Sciences and Nanosystems, Ca' Foscari University of Venice, Via Torino 155, Venezia Mestre 30172, Italy

[c] European Centre for Living Technologies (ECLT), San Marco 2940, Venice 30124, Italy. E-mail: alessandro.angelini@unive.it

residue in position 34, which alone makes up 80% of the free thiols in plasma.[7,24] The secondary structure of albumin is composed of 67% α-helix and no β-sheet elements, and the tertiary structure forms a monomer with a globular heart-shape for dimensions of 80 × 80 × 30 Å and a hydrodynamic diameter of approximately 5 nm.[9,24] The protein has three homologous domains, named I, II and III, with similar amino acid sequences and structures (Fig. 1).[25] Despite these similarities, each domain has its own unique interactions with the others, and the relative orientations create an asymmetrical module with several different ligand-binding sites distributed throughout its tertiary structure. Each domain contains two subdomains, denoted A and B, with four and six α-helices, respectively.[25] The overall structure is extremely stable over a wide pH range from 4.0 to 9.0, though its fold and shape can undergo a number of structural changes in response to changes in pH.[26]

The plasma concentration of albumin is the result of a sophisticated equilibrium among different synthesis, degradation, and distribution mechanisms in the body.[7,24] About 10–15 grams of albumin are produced in the liver per day. A healthy person of 70 kilograms has approximately 360 grams of albumin, one third of which is located in the plasma, with the remaining amount found in the extravascular compartment.[8,9] Several tissues catabolize an amount of albumin daily that is comparable to the produced amount, and this leaves a maximum circulatory half-life of 19 days in humans.[8,24] This long half-life is mainly related to its structural properties and its ability to bind FcRn.[27] Renal elimination is mostly limited by the molecular weight and net negative charge, while the pH-dependent recycling process mediated by the FcRn avoids intracellular lysosomal degradation. Mutagenesis and co-crystallization studies have revealed that the binding site for FcRn on albumin is localized on domain III and that it does not overlap with the receptor's IgG binding site.[27] Notably, the FcRn is also involved in the rescue of albumin from glomerular filtration.[27] In addition to FcRn, albumin interacts with other cell-surface receptors that are also responsible for its recycling, degradation, and intracellular transport.[8,28] All of these receptors, along with its hydrodynamic radius, overall negative charge, and high concentration, ultimately contribute to albumin homeostasis and its long half-life in humans, allowing it to take part in numerous and important physiological activities. These include the maintenance of the oncotic pressure and plasma pH levels as well as the binding, transport, and distribution of a large variety of ligands.[8,24] Both covalent and non-covalent binding to albumin are widely exploited, making it a suitable carrier for several different therapeutics. In particular, the capacity of albumin to extravasate from the bloodstream to reach the lymphatic system and accumulate in cancerous or inflamed areas has aroused a strong clinical interest in using it as a platform to extend the half-life of therapeutic peptides and small proteins.[8,9]

3. Albumin-binding small organic compounds

Serum albumin can intrinsically bind a large diversity of small endogenous and exogenous organic molecules, shielding their hydrophobic character and strongly increasing their solubility in plasma.[8,24] In particular, albumin acts as the key lipid delivery vehicle for the tissues, binding up to seven molecules of long fatty acids simultaneously (Fig. 1).[29] Two sites for binding medium-chain fatty acids have also been identified, yielding a total of nine distinct fatty acid binding locations distributed throughout its tertiary structure.[30] Short- to medium-length fatty acids (6 to 12 carbons) bind albumin with affinities between 0.5 and 60 μM, while the longest ones (14 to 18 carbons) have 10-fold higher affinities (below 50 nM).[31,32] The ability of serum albumin to bind long fatty acids with a high affinity inspired the use of post-translational acylation as a safe and natural platform for prolonging the half-life and the mode of action of peptides and small proteins.[5,6] Currently, fatty acids and derivatives represent the only successful example of non-covalent albumin-binding ligands that has led to the development of four approved drugs from Novo Nordisk: insulin detemir (Levemir®), insulin degludec (Tresiba®), liraglutide (Victoza® and Saxenda®), and semaglutide (Ozempic®), used for the treatment of diabetes mellitus (type 1 and 2) and/or obesity.[6,33] The properties and applications of lipid tails for extending the circulating half-life of small biotherapeutics has been extensively described elsewhere[6,33] and it will not be further discussed here.

In addition to fatty acids, serum albumin can bind numerous other small organic compounds by exploiting two major structurally dissimilar binding sites, known as Sudlow sites I and II (Fig. 1).[34,35] Site I comprises a central zone from which three distinct compartments extend, while site II is smaller and consists of a single narrow cleft.[35] Site I, also known as the warfarin–azapropazone binding site, usually accommodates dicarboxylic acids and/or bulky heterocycles carrying a central negative charge, whereas site II, also known as the benzodiazepine binding site, can discriminate ligands based on their size and stereoselectivity. Generally, aromatic

Fig. 1 Crystal structure of human serum albumin. The crystal structure of human serum albumin (PDB code 1AO6) representing the domains, subdomains, fatty acids and Sudlow's binding sites. The subdomains of albumin are shown in *dark blue* (IA), *light blue* (IB), *dark green* (IIA), *olive* (IIB), *orange* (IIIA) and *dark red* (IIIB). Legend: FA = fatty acid binding site.

This journal is © The Royal Society of Chemistry 2019

Med. Chem. Commun., 2019, **10**, 1068–1081 | **1069**

carboxylic acids with a peripheric negative charge, that is distantly located from the hydrophobic center, lodge in this site.[34,35] Because of their ability to non-covalently bind serum albumin, several organic moieties that are structurally similar to exogenous drugs (*e.g.* warfarin, ibuprofen and diazepam) and dye molecules (*e.g.* Evans blue) have also been used. For example, scientists at Genentech coupled several organic compounds, based on sulfonamide or phosphate ester moieties, to a peptide inhibitor of the coagulation factor VIIa (fVIIa).[36,37] Koehler *et al.* identified novel albumin-binding affinity tags by screening a focused library of compounds appended to a model tetrapeptide and evaluated the resulting compounds' ability to bind to serum albumin immobilized on a column.[36] The most promising hit, a naphthalene acyl sulfonamide tag (Fig. 2a), was coupled to a peptide with a potent affinity for fVIIa, and its activity was assessed *in vitro* and *in vivo*. The tagged peptide showed comparable affinities for fVIIa in the presence of human serum albumin, and when administered to rabbits, it exhibited a 4-fold increased plasma half-life compared to the peptide alone (Table 1).[36]

Similarly, Zoebel *et al.* envisioned identifying novel albumin-binding affinity tags by screening a focused library of phosphate esters,[37] mainly due to the fact that the diphenylcyclohexanol phosphate ester moiety (Fig. 2b) of the FDA-approved contrast agent Gadofosveset trisodium (trade name Vasovist, Ablavar) bound to site II of albumin.[38] The best conjugate retained its affinity for fVIIa and had a half-life 7-fold longer than the peptide tagged with naphthalene acyl sulfonamide moiety and 53-fold longer than the unmodified peptide in rabbits (Table 1).[37]

The 9-fluorenylmethoxycarbonyl (Fmoc) organic moiety (Fig. 2c) associates with multiple albumin species with affinities of around 20 μM. Importantly, the speed of hydrolysis of Fmoc is significantly reduced ($t_{1/2} \sim 24$ h) when incubated at 37 °C in aqueous buffer (pH 7.4) in the presence of a low concentration of serum albumin.[39] Fridkin and co-workers exploited these properties to generate Fmoc derivatives (named FMS) that could react with the amino groups of therapeutic peptides and proteins, converting them into inactive pro-drugs with desirable pharmacokinetic properties that

Fig. 2 Chemical structures of albumin-binding small organic compounds. a) naphthalene acyl sulfonamide moiety; b) diphenylcyclohexanol phosphate ester moiety; c) 9-fluorenylmethoxycarbonyl (Fmoc) moiety; d) Fmoc derivative linked to a 16-sulfanylhexadecanoic acid through a maleimide group; e) dicoumarol derivative with a maleimide group; f) Evans blue derivative with a maleimide group; g) divalent diflunisal-indomethacin moiety linked through a γGlu-Lys dipeptide coupled to a unit of 8-amino-3,6-dioxaoctanoic acid (O2Oc); h) lithocholic acid coupled to a γGlu linker; i) 6-(4-(4-iodophenyl)butanamido)hexanoate coupled to carboxyfluorescein through a D-Lys; j) A083/B134 and k) A099/B344.

Table 1 Albumin-binding small organic compounds

Cargo		Albumin-binding molecule	Conjugate			
Type	$\tau_{1/2}$		Affinity	$\tau_{1/2}$	Factor	Ref.
fVIIa inhibitor[†]	7.6 min (i.v.)[a]	Naphthalene acylsulfonamide	n.a.	30 min (i.v.)[a]	4[a]	36
	4.2 min (i.v.)[a]	Diphenylcyclohexanol phosphate ester	n.a.	222 min (i.v.)[a]	53[a]	37
Insulin[†]	3.3 h (i.v.)[b]	Fmoc derivative with a 16-sulfanyl hexadecanoic acid	3.9[c] μM*	17 h (i.v.)[b]	5[b]	40
Exendin-4[†]	2.8 h (s.c.)[b]	Dicoumarol derivative with maleimide	n.a.	19–22 h (s.c.)[b]	7–8[b]	41
	5.2 h (s.c.)[d]	Evans blue derivative with maleimide	n.a.	36.3 h (s.c.)[d]	7[d]	43
GLP-1[†]	n.a.	Diflunisal-γGlu-Lys(±O2Oc)-indomethacin	n.a.	5 h (s.c.)[d]	Liraglutide 4.4 h (s.c.)[d]	46
scFv[§]	20–30 min (i.v.)[d]	6-(4-(p-Iodophenyl) butanamido)	3.2[c], 3.6[d] μM	16.6 h (i.v.)[d]	33–50[d]	52
Fluorescein[‡]	4.6 min (i.v.)[d]	hexanoate	108[c], 118[d] nM[#] 330[c] nM[$]	495 min (i.v.)[d]	108[d]	48
Gd-DTPA[‡]	8.6 min (i.v.)[d]		3.3[c] μM	408 min (i.v.)[d]	47[d]	

Indicated terminal half-lives ($\tau_{1/2}$) and related factor of improvement were measured after intravenous (i.v.) or subcutaneous (s.c.) injection for rabbit (a), rat (b), human (c) and mouse (d) species. Indicated albumin-binding affinities were reported as published dissociation constant (K_d) or values calculated from published association constant (K_a) ($K_d = 1/K_a$; marked with an asterisk, *). Binding affinities determined using fluorescence polarization (FP) and isothermal titration calorimetry (ITC) are marked with a pound (#) and a dollar ($), respectively. Legend: n.a. = not available; † = peptide; § = protein; ‡ = chemical; fVIIa = coagulation factor VIIa; Fmoc = 9-fluorenylmethoxycarbonyl; exendin-4: peptide agonist of the glucagon like peptide 1 (GLP-1) receptor; GLP-1 = glucagon-like peptide 1; Lys = lysine; O2Oc = 8-amino-3,6-dioxaoctanoic acid; scFv = single-chain variable fragment; Gd-DTPA = gadopentetic acid (gadolinium (Gd) with diethylenetriaminepentaacetic acid (DTPA)).

could reactivate in body fluids. An insulin derivative (FMS₃-insulin) in which three FMS moieties were linked to three amine functional groups (Gly1 of chain A, Phe1 and Lys29 of chain B) recovered full biological potency only after four days of incubation in normal human serum at pH 7.4 and 37 °C. A single administration of this FMS₃-insulin to streptozocin (STZ)-treated rats lowered circulating glucose levels for a prolonged period of 45 h.[39] Afterwards, Sasson et al. developed an optimal reversible heterobifunctional agent that included a hydrolysable FMS derivative linked to a 16-sulfanylhexadecanoic acid with a higher affinity for albumin (Fig. 2d). An insulin derivative conjugated to this novel probe showed a half-life in rats exceeding more than five times that obtained for insulin alone (Table 1). When tested in mice, this derivative lowered glucose levels for a period of over 24 h.[40]

Han et al. has shown that conjugation of the small molecule dicoumarol (Fig. 2e), a former exogenous anticoagulant drug currently replaced by warfarin, to glucagon-like peptide-1 (GLP-1), an endogenous peptide hormone involved in the control of blood-glucose levels, resulted in an improved in vivo half-life in rats, which was approximately 2- and 7-fold greater than the long-acting GLP-1 analogs liraglutide and exendin-4, respectively (Table 1).[41] Importantly, the dicoumarol-GLP-1 conjugate retained receptor activation efficacy, exhibited improved albumin affinity and plasma stability, and had prolonged in vivo antidiabetic effects.[41]

Evans blue (EB) is an azo dye that binds to site I of serum albumin with low micromolar affinity (2.5 μM) and

has a long half-life in the blood.[35] Because of its ability to bind albumin, EB has been used clinically for many years to estimate patient blood plasma volume and extravascular protein leakage. Over the last few years, a series of functionalized EB derivatives have been developed as diagnostic MRI and PET imaging tracers for detecting lymph nodes and identifying tumor lesions.[42] Recently, novel chemical entities based on the structure of EB have been designed to extend the half-life of therapeutic peptides.[43] Conjugation of a truncated EB moiety (Fig. 2f) to the peptide exendin-4 (denoted as Abextide) showed prolonged drug release and an enhanced hypoglycemic effect in a mouse model of type 2 diabetes.[43] Abextide had a 7-fold extended half-life and sustained normal glycemia levels four times longer than the native exendin-4 (Table 1). An improved form, named Abextide II, displayed an even higher stability in both solution and powder form.[44] Recently, Zhu et al. showed that co-delivery of CpG adjuvant and peptide antigens conjugated to an EB derivative (denoted as AlbiVax) to lymph nodes induced potent and durable T-cell responses in mice. AlbiVax in combination with an immune checkpoint inhibitor significantly reduced the progression of multiple established tumors.[45]

In an elegant study, Jensen and co-workers investigated divalent small-molecule albumin binders as an approach for improving peptide pharmacokinetics.[46] Toward this goal, they performed a proof-of-principle study using GLP-1 analogues conjugated to either or both of the nonsteroidal anti-

inflammatory drugs diflunisal and indomethacin (Fig. 2g).[46] Diflunisal binds human albumin through both drug sites I and II with affinities of 3 μM, while indomethacin binds mainly to drug site I with an affinity of 0.7 μM.[35] Studies on GLP-1 analogues functionalized with diflunisal, indomethacin, or both showed that albumin affinity was increased for the divalent analogue as a result of an avidity effect that arose from combining multiple ligands targeting different sites on serum albumin. In lean mice, the divalent GLP-1 analogue showed superior biological efficacy and a promising gain in circulatory half-life comparable to that reported for liraglutide (Table 1).[46] Analogously to liraglutide, binding to albumin both prevented fast renal clearance and also protected the GLP-1 peptide from degradation, a process that occurs instantaneously in mouse plasma and is mediated by the dipeptidyl peptidase IV (DPP-IV).[46]

Bile acids and derivatives are examples of endogenous molecules used as albumin binders.[6,47] The most promising analogue, a lithocholic acid (Fig. 2h) conjugated to insulin (NN344), showed a certain affinity for albumin, and upon injection it formed subcutaneous deposits that were gradually released in the blood. When administered to pigs, NN344 controlled glucose levels for more than 24 h.[47] However, this molecule, as well as other cholic acid conjugates, appears not to have been further advanced, probably because of the low solubility of bile acids and their weak affinities for albumin.[47]

Finally, albumin ligands resembling the structures of known organic small molecules have been identified by Neri and co-workers by screening DNA-encoded chemical libraries.[48–51] Dumelin et al. identified several albumin-binding affinity tags all featuring a 4-phenylbutanoic acid moiety with different hydrophobic substituents on the phenyl ring. The best 4-(p-iodophenyl)butyric acid derivative, named 428-d-Lys-FAM (Fig. 2i), displayed a stable non-covalent interaction with both mouse and human serum albumin and exhibited comparable binding affinities (Table 1). Competition experiments made using known ligands indicated that the derivative binds to site II of albumin.[48] By using a larger DNA-encoded chemical library ($>10^5$ different compounds) composed of structurally diverse carboxylic acid building blocks, Franzini et al. identified several ligands capable of binding human serum albumin with sub-nanomolar binding affinities (A083/B134: 0.4 nM; A077/B286: 0.7 nM; A083/B321: 0.9 nM).[50] Replacement of either of the building blocks by an acetamide group drastically decreased the affinity of the compounds for albumin. Particularly, the 5-bromoindole moieties were critical for albumin binding, and their substitution raised the binding affinities by more than 2000-fold. To the best of our knowledge, compound A083/B134 (Fig. 2j) is the tightest small-molecule binder for human albumin reported so far.[50] By applying parallel affinity screening of a DNA-encoded chemical library against rat, bovine, and human serum albumin, Franzini et al. identified novel small-molecules with distinctive binding specificities for the individual albumins.[51] Compounds with a binding preference to one of the proteins and ligands with an affinity to all three targets were

isolated. For each serum albumin, the authors were able to identify a small molecule that bound with an affinity below 10 nM and exhibited at least 10-fold specificity over the other two proteins. Interestingly, the human selective A099/B344 (5.4 nM) is structurally distinct from the previously described small molecules binding human albumin (Fig. 2k).[51]

Even though numerous sub-nanomolar albumin binders have been recently isolated from these DNA-encoded chemical libraries, only a few 4-(p-iodophenyl)butyric acid derivatives have been characterized in vivo.[48] Pharmacokinetic analyses of the best 4-(p-iodophenyl)butyric acid derivative, named Albutag, revealed a long half-life in the bloodstream of up to 24 h after injection.[48] Attaching Albutag to an engineered therapeutic antibody fragment (scFv-F8) resulted into a >30-fold longer half-life and higher tumor uptake in a mouse model (Table 1).[52] Although efficacious in prolonging the pharmacokinetic properties of small molecules or recombinant proteins,[48,52] Albutag appears to have found its major success as portable albumin-binding moiety for the delivery of contrast agents for biomedical imaging. Conjugating Albutag to fluorescein derivatives used for angiographic analysis of the retina increased their half-life by approximately 100-fold in mice (Table 1).[48] Similarly, linking Albutag to the magnetic resonance imaging (MRI) contrast agent gadolinium-diethylenetriaminepentaacetic acid (Gd-DTPA, Magnevist) enhanced its half-life by approximately 50-fold (Table 1).[48] Analogue approaches have been applied to enhance the tumor-to-non-tumor ratio of multiple tumor-targeting contrast agents.[53] In vivo single-photon emission computed tomography (SPECT) imaging of an Albutag conjugated to a folic acid that was modified with a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) chelator for coordination of a therapeutic radioisotope (cm09) showed 5- to 6-fold higher tumor-to-kidney ratios than those obtained with folate radioconjugated ligands that lacked an albumin-binding entity.[53] Radionuclide therapy in tumor-bearing mice had positive results in terms of tumor remission and significantly prolonged survival times when compared with untreated controls.[53] Babich and colleagues used Albutag to develop a dual-targeting radioiodinated ligand (RPS-027) that bound to both prostate-specific membrane antigen (PSMA) and albumin to enable longer blood circulation times.[54] When tested in a preclinical model of prostate cancer, RPS-027 demonstrated a favorable tumor-to-kidney ratio and had a promising therapeutic profile that made it suitable for the targeted radiotherapy (TRT) of prostate cancer.[54] The same research group has recently generated a novel class of trifunctional ligands, consisting of the high-affinity PSMA-binding domain, the Albutag, and the DOTA chelator for radiometals, to facilitate the modification of the three moieties independently and ultimately enable the generation of spatial optimized conjugates.[55] In vivo small-animal positron emission tomography (μPET) imaging demonstrated that the trifunctional ligands had high and persistent tumor uptake with absorbed doses that were four times greater than those observed for a similar compound lacking the albumin-binding moiety.[55] A further optimized trifunctional ligand, named

1072 | Med. Chem. Commun., 2019, 10, 1068–1081

This journal is © The Royal Society of Chemistry 2019

^{68}Ga-RPS-072, had an order of magnitude higher binding affinity for albumin, showed a significantly delayed blood clearance, and had a superior tumor-to-kidney ratio than those of the other radioligands tested in the cancer prostate xenograft model.[56] Recently, Umbricht *et al.* used Albutag to develop novel long-circulating albumin-binding PSMA-targeting PET radioligands by substituting DOTA with 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid (NODAGA), a chelator that has been shown to increase the *in vivo* stability of longer-lived radionuclides.[57] A PSMA-targeting PET radioligand bearing NODAGA (PSMA-ALB-89) had a more favorable *in vivo* stability and increased tumor accumulation when compared to the same ligand conjugated to DOTA (PSMA-ALB-56).[57]

4. Albumin-binding peptide ligands

Alternatively to small molecules, an increasing number of peptides have been used as albumin-binding molecules. Indeed, albumin is known to bind not only low molecular weight molecules, but also to peptides and proteins such as insulin, bradykinin, and interferons, and several hundreds of other binders have been identified or predicted.[58,59] This observation suggested the application of *in vitro* techniques for screening peptides that can bind albumin with a high affinity and that could be used as carriers for half-life extension.[60–63] In contrast to small chemical moieties, albumin-binding peptides can easily be fused to any protein or peptide, either recombinantly or chemically during solid-phase synthesis.[64]

Several linear peptides binding human albumin with nanomolar affinities have been identified by Revets and Boutton (WO2011095545).[65] The best binder was an 18-amino acids peptide named 89D03 (Ac-WWEQDRDWDFDVFGGGTP-NH$_2$) (Fig. 3a) that binds tightly to human albumin (15 nM).[65] Fusing 89D03 to the C-terminus of an anti-HER2 nanobody developed by Ablynx (clone 5F7) prolonged its half-life by more than 7-fold in cynomolgus monkeys. The further addition of two 89D03 peptides in tandem to the C-terminus of the nanobody extended the half-life by more than 3 days (Table 2).[65]

Recently, Heinis and co-workers engineered a novel chimeric albumin-binding molecule consisting of a fatty acid combined with a short linear peptide comprised of seven amino acids (Fig. 3b).[62] By applying iterative rounds of amino acid substitution and affinity measurement by fluorescence polarization (FP), Zorzi *et al.* evolved an acylated heptapeptide tag, named F-tag, able to bind human, rat, and rabbit albumin with affinity values of 39, 220, and 320 nM, respectively (Table 2).[62] Binding experiments revealed that the N-terminal fluorescein moiety used for FP analysis contributed, along with the palmitate moiety and the specific peptide sequence, to the affinity for albumin. Despite the presence of the long hydrophobic tail of the palmitic acid and the fluorescein, the lipidated F-tag peptide exhibits a high solubility due to the four negative charges in the peptide sequence. Importantly, the F-tag could easily be appended to cargo peptides by automated synthesis on standard peptide synthesizers. Pharmacokinetic experiments showed that the acylated heptapeptide extended the circulation time of two different bicyclic peptides in rats and rabbits by around 25-fold, reaching half-lives of 7 and 5 h, respectively (Table 2).[62] Furthermore, the presence of the F-tag improved the proteolytic stability of the cargo peptides over the non-tagged peptides. Finally, conjugation of the F-tag to a picomolar bicyclic peptide inhibitor of the activated human coagulation factor XII (hFXIIa) led to an efficient blockage of the intrinsic coagulation pathway in rabbits for as long as 8 h, suggesting a potential application in humans as anti-thrombotic drug.[62]

Dennis *et al.* used phage display to isolate cyclic peptides bearing two fixed cysteine residues and varying loop sizes that bind albumin with high affinity.[60] They selected several disulfide-cyclized binders for rabbit, rat, and human albumin, and a clone sharing high binding for all three species was further subjected to affinity maturation. The best albumin binder was an 18-amino acids peptide called SA21 (Ac-RLIEDIC̲LPRWGC̲LWEDD-NH$_2$) (Fig. 3c) that bound albumin from different species with nanomolar affinities (Table 2). The pharmacokinetics of SA21 alone was tested in rabbits and showed an 18-fold prolonged half-life compared to an unrelated control peptide. The fusion of SA21 to the C-terminus of an antigen-biding antibody fragment (Fab) efficiently prolonged the half-life of the protein up to 37-fold in rabbits and 26-fold in mice (Table 2).[60] The importance of developing high-affinity peptides was confirmed in a follow-up study where SA21 variants with 5- to 10-fold weaker binding to albumin showed two to three times shorter half-lives.[66] The capacity of SA21 to improve the half-life of bicyclic peptides was recently investigated by Heinis and co-workers. Through the chemical conjugation of SA21 to UK18, a bicyclic peptide inhibitor of human urokinase-type plasminogen activator (huPA), Angelini *et al.* showed that non-covalent binding to albumin could improve both pharmacokinetic and metabolic characteristics of the peptide conjugates without interfering with the binding of the corresponding protein target.[67] Experiments in mice revealed a ~50-fold prolonged bicyclic peptide circulation time, and the conjugate remained fully intact and functional for more than 48 h (Table 2).[67] In a second study, Pollaro *et al.* showed that the same conjugate diffused in high concentrations into tumor tissues and was not limited by the high affinity of SA21 for the endogenous murine albumin.[68] The SA21 peptide was later applied to other small proteins and exhibited promising preclinical results.[69,70]

Recently, Neri and co-workers identified specific macrocyclic binders against human serum albumin by exploiting a novel DNA-encoded chemical library displaying multiple diversity elements into one side of a structurally defined β-sheet scaffold (Fig. 3d).[63] The two enriched compounds featured the presence of diverse chemical element combinations and revealed binding affinities in the single-digit micromolar range (6.6 and 22 μM).[63] Although not yet characterized *in vivo*, these macrocycles have high potential for the selective *in vivo* delivery of payloads to tumors.

Fig. 3 Chemical structures of albumin-binding peptide ligands. a) linear peptide 89D03: Ac-WWEQDRDWDFDVFGGGTP-NH₂; b) acylated heptapeptide F-tag: fluorescein-EYEK(palmitate)EYE-NH₂; c) disulfide cyclized peptide SA21: Ac-RLIEDICLPRWGCLWEDD-NH₂; d) head-to-tail cyclized peptide HSA-1: AK*K*PGK*AK*PG with variable lysine (K*).

5. Albumin-binding protein domains

Protein domains usually have a large interaction interface with their target, leading to high binding affinities and specificities – key features for the development of albumin binders. Several albumin-binding domains (ABDs) were discovered in bacterial proteins, the best-characterized of which are derived from protein G of *Streptococcus* strain GI48 and from protein PAB of *Finegoldia magna*. These ABDs have 59% homologous amino acid sequence identities, are very stable despite their small size (~5 kDa), and fold into a three-helix-bundle domain that interacts with serum albumin primarily along one of its faces.[71] Importantly, both ABDs target the same binding site on domain II of human serum albumin (Fig. 4a) and do not overlap or interfere with binding to the FcRn-binding site on albumin, which is located in domain III (Fig. 4b). The affinity of ABDs for albumin was strongly improved by phage display and rational design, reaching a binding affinity for human albumin of 50–500 fM (variant ABD035).[72] This engineered high-affinity variant, which

1074 | *Med. Chem. Commun.*, 2019, **10**, 1068–1081

This journal is © The Royal Society of Chemistry 2019

Table 2 Albumin-binding peptide ligands

Cargo		Albumin-binding molecule	Conjugate		Factor	Ref.
Type	$\tau_{1/2}$		Affinity	$\tau_{1/2}$		
Anti-HER2[§]	4.3 h (i.v.)[a]	89D03 (15[b] nM)	n.a.	Single copy: 31.2 h (i.v.)[a]	7[a]	65
				Double copy: 84.5 h (i.v.)[a]	20[a]	
huPA inhibitor[†]	18 min (i.v.)[c]	F-tag	168[b], 780[c] nM	7.4 h (i.v.)[c]	25[c]	62
hFXIIa inhibitor[†]	13 min (i.v.)[d]	(39[b], 220[c], 320[d] nM)	224[a], 1600[d] nM	5.2 h (i.v.)[d]	24[d]	
Fab[§]	53 min (i.v.)[d]	SA21	320[d] nM	32.4 h (i.v.)[d]	37[d]	60
	24 min (i.v.)[e]	(467[b], 266[c], 320[d], 7[e] nM)		10.4 h (i.v.)[e]	26[e]	
huPA inhibitor[†]	30 min (i.v.)[e]		354[b], 14[e] nM	24 h (i.v.)[e]	48[e]	67
Exendin-4[†]	30 min (i.v.)[c]		610[a], 1560[b], 210[c] nM	2 d (i.v.)[a]	22[c]	83
				11 h (i.v.)[c]		

Indicated terminal half-lives ($\tau_{1/2}$) and related factor of improvement were measured after intravenous (i.v.) or subcutaneous (s.c.) injection for monkey (a), human (b), rat (c), rabbit (d) and mouse (e) species. Indicated albumin-binding affinities were reported as published dissociation constant (K_d). Legend: n.a. = not available; † = peptide; § = protein; HER2 = receptor tyrosine-protein kinase erbB-2; huPA = human urokinase-type plasminogen activator; hFXIIa = activated human coagulation factor XII; Fab = antigen-binding fragment.

forms the basis of Albumod, improved the pharmacokinetics of various recombinantly fused proteins, including soluble receptors,[73] cytokines,[74] bispecific single-chain diabodies (scDb),[75,76] lipocalin-derived anticalin® proteins,[77] targeted immunotoxins,[78,79] and affibody® scaffold molecules.[80–82] In a recent study, Levy et al. compared two exendin-4 conjugates obtained by appending either the optimized variant ABD035 or a shorter version of the cyclic peptide SA21 to its C-terminus. Very different affinities for albumin were reported between the two formats, ranging from 5 to 40 pM or 200 to 1500 nM, respectively.[83] The SA21-exendin-4 conjugate showed a 10-fold higher potency in vitro compared to the ABD variant, most likely related to differences in steric hindrance. In contrast, the remarkable differences in albumin affinity strongly impacted the pharmacokinetics in monkeys, which resulted in a 7-fold longer half-life for the ABD-exendin-4 conjugate compared to the SA21 variant (14 days vs. 2 days) that potentially counterbalance its reduction in activity, while comparable values were obtained in rats (Tables 2 and 3).[83] A de-immunized ABD variant, named ABD094, retained a high affinity for different serum albumin species and is currently being tested in the clinic (NCT02690142).[82]

Recently, Jacobs et al. have engineered a novel three-helix-bundle albumin-binding domain, named ABDCon, that exhibits high binding affinity for different serum albumins (Table 3) while maintaining a high solubility and thermal stability (91 °C).[84] The fusion of ABDCon to a fibronectin domain (Fn3) resulted in a long terminal half-life ranging from 3 to 8 days in mice and cynomolgus monkeys, respectively (Table 3).[84] The capacity of ABDs for prolonging the half-life of conjugates does not correlate with further increased binding affinities for albumin, suggesting an intrinsic limit connected to either the FcRn-mediated recycling or albumin half-life.[76,84]

Other albumin-binding domains were recently engineered from the bacterial protein Sso7d from the hyperthermophilic archaeon Sulfolobus solfataricus. Sso7d is a small, cysteine-free DNA-binding protein (~7 kDa, 63 amino acids) with a melting temperature of 98 °C. The three-dimensional structure consists of an oligonucleotide-binding (OB) fold with an incomplete five-stranded β-barrel closed off by a C-terminal α-helix (Fig. 4c).[85] Traxlmayr et al. applied yeast display technology to engineer two high-affinity clones, M11.1.2 and M18.2.5, that bound mouse serum albumin with affinities of 7 and 26 nM, respectively.[86] Sso7d binders against multiple

Fig. 4 Three-dimensional structures of albumin-binding protein ligands. a) crystal structure of a bacterial ABD scaffold (GA, red) in complex with human serum albumin (grey, PDB code 1TF0); b) crystal structure of the human neonatal Fc receptor (FcRn, light orange) in complex with human serum albumin (grey, PDB code 4N0F); c) solution structure of the bacterial protein Sso7d (dark blue, PDB code 1SSO); d) crystal structure of a DARPin protein domain (dark green, PDB code 1 MJ0); e) crystal structure of a single-domain antibody (dAb, dark orange, PDB code 3BD3); f) crystal structure of the fab domain (CA645, light blue) in complex with human serum albumin (grey, PDB code 5FUO); g) crystal structure of a nanobody (Nb.b201, brown) in complex with human serum albumin (grey, PDB code 5VNW); h) crystal structure of a VNAR domain (E06, light green) in complex with human serum albumin (grey, PDB code 4HGM).

This journal is © The Royal Society of Chemistry 2019

Med. Chem. Commun., 2019, 10, 1068–1081 | 1075

Table 3 Albumin-binding small protein scaffolds

Cargo		Albumin-binding molecule	Conjugate			
Type	$\tau_{1/2}$		Affinity	$\tau_{1/2}$	Factor	Ref.
Exendin-4[†]	30 min (i.v.)[a]	ABD035 (18[a], 123[b], 16[c] pM)	8[a], 40[b], 5[c] pM	16 h (i.v.)[a] 14 d (i.v.)[b]	32[a]	83
Fibronectin domain[§]	n.a.	ABDCon (61[b], 75[c], 3200[d] pM)	0.7[c], 1.8[d] nM	193 h (i.v.)[b] 60 h (i.v.)[d]	n.a.	84
DARPins drug candidate[§]	0.008 d (i.v.)[b]	DARPins (91–266[a], 63–110[b], 11–21[c], 56–142[d], 77–185[e] nM)	n.a.	2.7–20.7 d (i.v.)[b] 21–82 h (i.v.)[d]	>330[b]	89
IL-1rα[§]	2 min (i.v.)[d]	AlbudAbs	34–600 nM[a,c,d]	4.3 h (i.v.)[d]	130[d]	91
IFN-α2[§]	1.2 h (i.v.)[a] 1.5 h (s.c.)[a]			22.6 h (i.v.)[a] 28.3 h (s.c.)[a]	19[a]	92
Anti-TNFR1[§]	n.a.			3.3–23.2 h (i.v.)[d]	n.a.	93
Exendin-4[†]	2.5 h (s.c.)[c]			6–10 d (s.c.)[c]	58–96[c]	94
Fab[§]	n.a.	dsFv CA645 (54[a], 3.3[b], 4.6[c], 7.1[d], 162[f] nM)	n.a.	7.9 d (i.v.)[b] 2.6 d (i.v.)[d]	n.a.	96, 97
Anti-TNF[§]	35–54 min (i.v.)[d]	Nanobody (22[c] nM)	n.a.	2.2 d (i.v.)[d]	91[d]	99
Anti-IL-6R[§]	4.3 h (i.v.)[b]			1.7–6.6 d (i.v.)[b]	9–37[b]	100
Naïve VNAR[§]	0.15 h (i.v.)[d]	VNAR (E06) (3[a], 1[c], 6[d] nM)	n.a.	22–25 h (i.v.)[a] 164–210 h (i.v.)[b] 21–33 h (i.v.)[d]	140–220[d]	102

Indicated terminal half-lives ($\tau_{1/2}$) and related factor of improvement were measured after intravenous (i.v.) or subcutaneous (s.c.) injection for rat (a), monkey (b), human (c), mouse (d), dog (e) and rabbit (f) species. Indicated albumin-binding affinities were reported as published dissociation constant (K_d). Legend: n.a. = not available; † = peptide; § = protein; DARPins = designed ankyrin repeat proteins; IL-1rα = interleukin-1 receptor antagonist; IFN-α2 = interferon alpha-2; TNFR1 = tumor necrosis factor receptor 1; TNF = tumor necrosis factor; IL-6R = interleukin-6 receptor; VNAR = variable domain derived from cartilaginous fish's immunoglobulin like new antigen receptors.

albumin species have also been engineered by Fisk and colleagues.[87] The tighter binder (13A8) had an affinity for albumin of 2.1 μM when displayed on the surface of phage and could discriminate among closely related human and bovine serum albumins.[87] Even though numerous Sso7d albumin binders have recently been isolated, none have been characterized *in vivo*. Given their small size and high thermal stability, we expect the Sso7d-derived albumin-binding domains to have pharmacokinetic properties similar to other ABD domains.

Another strategy is the development of albumin-binding designed ankyrin repeat proteins (DARPins®).[88] These scaffolds are derived from naturally occurring ankyrin proteins comprising up to 29 consecutive, tightly packed repeat modules. Each repeat is usually 33-amino acids long and forms a structural unit consisting of a β-turn followed by two antiparallel α-helices. DARPins comprise usually 4 to 5 repeat motifs with molecular masses of about 14 and 18 kDa, respectively (Fig. 4d). Similar to other albumin-binding domains, DARPins exhibit favorable biophysical properties, including a high thermal stability.[88] Using ribosome display technology, Binz and co-workers selected several DARPin domains with mid-nanomolar affinities to different serum albumins

(Table 3).[89] Recombinant fusion of the best-engineered serum albumin-binding domain to a DARPin drug candidate led to a >300-fold prolonged half-life in cynomolgus monkey (Table 3).[89] Interestingly, constructs including two DARPin albumin-binding domains with different affinities (2.5 and 11.2 nM) exhibited comparable serum half-lives in mice, indicating that a low nanomolar threshold affinity is sufficient for albumin-binding proteins, as half-lives are not extended when higher-affinity or higher-valency molecules are used.[76,89]

Similarly, antibody fragments have also been engineered as albumin binders with promising results. Tomlinson and co-workers applied phage display to isolate small (~12 kDa), stable, and fully human domain antibodies (dAbs) against human, mouse, and rat albumins (Fig. 4e).[90,91] Numerous dAbs, also known as AlbudAbs, were isolated with different degrees of species cross-reactivities and affinities (34–600 nM). Pharmacokinetic analyses with the high binding affinity AlbudAbs revealed half-lives similar to that of albumin itself.[91] Fusion of AlbudAb to an interleukin-1 receptor antagonist (IL-1ra) exhibited similar *in vitro* potency, improved *ex vivo* stability, and a ~130-fold longer *in vivo* half-life compared to IL-1ra alone (Table 3). The half-life improvement

1076 | *Med. Chem. Commun.*, 2019, **10**, 1068–1081

This journal is © The Royal Society of Chemistry 2019

resulted in an improved efficacy of the fusion when tested in a mouse model of arthritis.[91] The AlbudAb platform was recently applied to enhance the half-life of other small proteins, such as the interferon alpha-2 (IFN-α2)[92] and an antibody domain antagonist for the mouse tumor necrosis factor receptor 1 (TNFR1),[93] both of which have an increased half-life and a retained activity when compared to the small proteins alone (Table 3).[92,93] The AlbudAb technology, now belonging to GlaxoSmithKline (GSK), has been recently tested in phase I in humans, wherein a fusion of AlbudAb to exendin-4 (GSK2374697) resulted in a 58- to 96-fold increase in the elimination half-lives in healthy patients (Table 3).[94] While the AlbudAb has been mainly applied as genetic fusion, a recent study demonstrated that it can also be chemically linked representing a significant advance in the use of AlbudAb to extend the half-life of small biotherapeutics.[95] The chemical conjugation of AlbudAb to an apelin-modified peptide agonist (MM202) resulted in an improved plasma half-life over both its parent compound and the endogenous agonist.[95] Notably, the MM202-AlbudAb conjugate retained a high binding affinity to the human apelin receptor as well as functional activity in vitro and in vivo.[95]

Furthermore, Adams et al. identified a Fab, named CA645, with consistent cross-species reactivity and low nanomolar affinities for multiple serum albumins (Table 3).[96] The crystal structure of CA645 in complex with human serum albumin revealed that the Fab binds to domain II (Fig. 4f). Importantly, the recognized epitope is distal from the main fatty acid and drug-binding sites and does not inhibit the binding of serum albumin to FcRn. When tested in mice, the CA645 exhibited a half-life of 3.5 days, 175-fold longer than a non-albumin-binding Fab variant. Interestingly, in line with what has been previously observed with other albumin-binding domains, a >140-fold reduction in the affinity for mouse serum albumin from 2.2 nM to 316 nM had no effect on the pharmacokinetic profile and half-life. Even with a reduction in affinity up to 62 μM, the half-life was still extended up to one day.[96] Construction of a bispecific antibody format (Fab-dsFv), obtained by fusing an anti-albumin Fv domain (645Fv) derived from the humanized CA645 to another Fab with a different target specificity, led to serum half-lives of 2.6 days in mice and 7.9 days in cynomolgus monkeys (Table 3).[97]

A recent trend is the development of albumin binders based on the small (12–15 kDa) and stable variable domain of the heavy-chain-only (VHH) antibodies (Nanobodies®) naturally occurring in the Camelidae family.[98] Structural analysis showed that nanobodies present a typical immunoglobulin variable domain (IgV) fold comprising nine β-strands and a conserved disulfide bond. As in traditional IgV domains, nanobodies contain three hypervariable loops connected by four conserved framework regions. Ablynx's proprietary half-life extension technology is based on a nanobody that binds to human serum albumin with an affinity of 22 nM. Fusion of this albumin-binding nanobody to two anti-TNF-targeting VHH domains led to a bispecific three-domain nanobody with a 90-fold prolonged half-life compared to a monomeric

anti-TNF nanobody (Table 3) as well as superior therapeutic efficacy when tested in a mouse model of arthritis.[99] Similarly, linkage of the albumin-binding nanobody to a VHH domain targeting the interleukin-6 receptor (IL-6R) resulted in a bispecific two-domains nanobody (ALX-0061) that exhibited high potency in vitro as well as promising in vivo efficacy when tested in non-human primate models of IL-6-induced inflammation and arthritis.[100] The pharmacokinetic profile of ALX-0061 in cynomolgus monkeys showed half-lives ranging from 1.7 to 6.6 days, whereas the non-extended anti-IL-6R domain was cleared in few hours (Table 3).[100] ALX-0061 is currently in clinical development for the treatment of autoimmune diseases such as rheumatoid arthritis. Moreover, a novel nanobody molecule (Nb.b201) with a modest affinity for human serum albumin (430 nM) and no binding to the related mouse serum albumin has recently been described by Kruse and co-workers.[101] The crystal structure of the protein complex revealed that Nb.b201 recognized a convex protrusion on the surface of human albumin (Fig. 4g).[101] However, no data have been reported on the pharmacokinetic profile of this molecule.

Finally, the variable domain (VNAR) derived from the immunoglobulin new antigen receptor (IgNAR) of cartilaginous fish (IgNAR) represents another example of a single antibody scaffold that has been successfully engineered to bind albumin with a high affinity.[102] Similarly to VHHs, VNARs are small (~12 kDa) and stable proteins with a β-sandwich fold.[103] By screening an immunized VNAR phage library, Müller et al. have selected multiple clones with high affinities against different albumin species.[102] The lead VNAR clone (E06) exhibited single digit nanomolar affinities for different serum albumins (Table 3) and binds a non-overlapping epitope on domain II of serum albumin (Fig. 4h), enabling it to retain binding to FcRn. When linked to a random naïve VNAR domain in different orientations, clone E06 prolonged the half-life of the fusions up to one day in rats and mice as well as more than seven days in cynomolgus macaques (Table 3).[102]

6. Conclusions

The use of non-covalent albumin-binding ligands has proven to be an effective strategy to prolong the in vivo plasma residence time of numerous small biotherapeutics. When bound to albumin, the peptides and small proteins are sterically shielded from proteolytic degradation and protected from rapid renal filtration due to the relatively larger hydrodynamic volume of albumin and its ability to bind the recycling FcRn. Moreover, the choice of a reversible, non-covalent association with serum albumin allows for the detachment of the biotherapeutic, facilitating its interaction with its target as well as its penetration and diffusion into small regions that are not otherwise accessible to larger molecules.

The ability of albumin to bind molecules of such different natures through multiple sites distributed throughout its tertiary structure has led to the development of numerous

This journal is © The Royal Society of Chemistry 2019

Med. Chem. Commun., 2019, 10, 1068–1081 | 1077

extension tags, each with its own advantages and disadvantages. Many have been tested in preclinical models, while others are already in clinical use. The choice of one albumin-binding ligand at the expense of another depends primarily on the intrinsic properties of the bioactive molecule and its clinical application. Therefore, an albumin-binding ligand must be carefully evaluated for each biotherapeutic and the consideration of other parameters besides half-life, such as biodistribution, penetration and accumulation in tissue, and immunogenicity, are important factors.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

References

1 R. Vazquez-Lombardi, T. G. Phan, C. Zimmermann, D. Lowe, L. Jermutus and D. Christ, Challenges and opportunities for non-antibody scaffold drugs, *Drug Discovery Today*, 2015, **20**(10), 1271–1283.

2 J. R. Kintzing, M. V. Filsinger Interrante and J. R. Cochran, Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer Treatment, *Trends Pharmacol. Sci.*, 2016, **37**(12), 993–1008.

3 A. Henninot, J. C. Collins and J. M. Nuss, The Current State of Peptide Drug Discovery: Back to the Future?, *J. Med. Chem.*, 2018, **61**(4), 1382–1414.

4 D. Stepensky, Pharmacokinetics of Toxin-Derived Peptide Drugs, *Toxins*, 2018, **10**(11), 483.

5 R. E. Kontermann, Half-life extended biotherapeutics, *Expert Opin. Biol. Ther.*, 2016, **16**(7), 903–915.

6 S. B. van Witteloostuijn, S. L. Pedersen and K. J. Jensen, Half-Life Extension of Biopharmaceuticals using Chemical Methods: Alternatives to PEGylation, *ChemMedChem*, 2016, **11**(22), 2474–2495.

7 G. Fanali, A. di Masi, V. Trezza, M. Marino, M. Fasano and P. Ascenzi, Human serum albumin: from bench to bedside, *Mol. Aspects Med.*, 2012, **33**(3), 209–290.

8 D. Sleep, Albumin and its application in drug delivery, *Expert Opin. Drug Delivery*, 2015, **12**(5), 793–812.

9 M. T. Larsen, M. Kuhlmann, M. L. Hvam and K. A. Howard, Albumin-based drug delivery: harnessing nature to cure disease, *Mol. Cell. Ther.*, 2016, **4**, 3.

10 W. L. DeLano, M. H. Ultsch, A. M. de Vos and J. A. Wells, Convergent solutions to binding at a protein-protein interface, *Science*, 2000, **287**(5456), 1279–1283.

11 C. Mersich, W. Billes and A. Jungbauer, Identification of a ligand for IgG-Fc derived from a soluble peptide library

based on fusion proteins secreted by S. cerevisiae, *Biotechnol. J.*, 2007, **2**(6), 672–677.

12 S. Menegatti, M. Hussain, A. D. Naik, R. G. Carbonell and B. M. Rao, mRNA display selection and solid-phase synthesis of Fc-binding cyclic peptide affinity ligands, *Biotechnol. Bioeng.*, 2013, **110**(3), 857–870.

13 J. T. Sockolosky, S. Kivimae and F. C. Szoka, Fusion of a short peptide that binds immunoglobulin G to a recombinant protein substantially increases its plasma half-life in mice, *PLoS One*, 2014, **9**(7), e102566.

14 M. Hutt, A. Farber-Schwarz, F. Unverdorben, F. Richter and R. E. Kontermann, Plasma half-life extension of small recombinant antibodies by fusion to immunoglobulin-binding domains, *J. Biol. Chem.*, 2012, **287**(7), 4462–4469.

15 F. Unverdorben, M. Hutt, O. Seifert and R. E. Kontermann, A Fab-Selective Immunoglobulin-Binding Domain from Streptococcal Protein G with Improved Half-Life Extension Properties, *PLoS One*, 2015, **10**(10), e0139838.

16 J. M. Donaldson, C. Zer, K. N. Avery, K. P. Bzymek, D. A. Horne and J. C. Williams, Identification and grafting of a unique peptide-binding site in the Fab framework of monoclonal antibodies, *Proc. Natl. Acad. Sci. U. S. A.*, 2013, **110**(43), 17456–17461.

17 J. Seijsing, M. Lindborg, I. Hoiden-Guthenberg, H. Bonisch, E. Guneriusson and F. Y. Frejd, *et al.*, An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein, *Proc. Natl. Acad. Sci. U. S. A.*, 2014, **111**(48), 17110–17115.

18 A. R. Mezo, K. A. McDonnell, C. A. Hehir, S. C. Low, V. J. Palombella and J. M. Stattel, *et al.*, Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn, *Proc. Natl. Acad. Sci. U. S. A.*, 2008, **105**(7), 2337–2342.

19 J. T. Sockolosky, M. R. Tiffany and F. C. Szoka, Engineering neonatal Fc receptor-mediated recycling and transcytosis in recombinant proteins by short terminal peptide extensions, *Proc. Natl. Acad. Sci. U. S. A.*, 2012, **109**(40), 16095–16100.

20 S. C. Penchala, M. R. Miller, A. Pal, J. Dong, N. R. Madadi and J. Xie, *et al.*, A biomimetic approach for enhancing the in vivo half-life of peptides, *Nat. Chem. Biol.*, 2015, **11**(10), 793–798.

21 C. Gronwall, A. Sjoberg, M. Ramstrom, I. Hoiden-Guthenberg, S. Hober and P. Jonasson, *et al.*, Affibody-mediated transferrin depletion for proteomics applications, *Biotechnol. J.*, 2007, **2**(11), 1389–1398.

22 J. Zhang, B. A. Williams, M. T. Nilsson and J. C. Chaput, The evolvability of lead peptides from small library screens, *Chem. Commun.*, 2010, **46**(41), 7778–7780.

23 J. H. Lee, J. A. Engler, J. F. Collawn and B. A. Moore, Receptor mediated uptake of peptides that bind the human transferrin receptor, *Eur. J. Biochem.*, 2001, **268**(7), 2004–2012.

24 T. Peters, *All About Albumin: Biochemistry, Genetics, and Medical Applications*, Academic Press, San Diego, CA, 1996, p. 432.

1078 | *Med. Chem. Commun.*, 2019, **10**, 1068–1081

This journal is © The Royal Society of Chemistry 2019

25 S. Curry, Lessons from the crystallographic analysis of small molecule binding to human serum albumin, *Drug Metab. Pharmacokinet.*, 2009, **24**(4), 342–357.

26 M. Dockal, D. C. Carter and F. Ruker, Conformational transitions of the three recombinant domains of human serum albumin depending on pH, *J. Biol. Chem.*, 2000, **275**(5), 3042–3050.

27 K. M. Sand, M. Bern, J. Nilsen, H. T. Noordzij, I. Sandlie and J. T. Andersen, Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics, *Front. Immunol.*, 2014, **5**, 682.

28 A. M. Merlot, D. S. Kalinowski and D. R. Richardson, Unraveling the mysteries of serum albumin-more than just a serum protein, *Front. Physiol.*, 2014, **5**, 299.

29 G. J. van der Vusse, Albumin as fatty acid transporter, *Drug Metab. Pharmacokinet.*, 2009, **24**(4), 300–307.

30 A. A. Bhattacharya, T. Grune and S. Curry, Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin, *J. Mol. Biol.*, 2000, **303**(5), 721–732.

31 A. A. Spector, Fatty acid binding to plasma albumin, *J. Lipid Res.*, 1975, **16**(3), 165–179.

32 U. Kragh-Hansen, H. Watanabe, K. Nakajou, Y. Iwao and M. Otagiri, Chain length-dependent binding of fatty acid anions to human serum albumin studied by site-directed mutagenesis, *J. Mol. Biol.*, 2006, **363**(3), 702–712.

33 E. M. Bech, S. L. Pedersen and K. J. Jensen, Chemical Strategies for Half-Life Extension of Biopharmaceuticals: Lipidation and Its Alternatives, *ACS Med. Chem. Lett.*, 2018, **9**(7), 577–580.

34 G. Sudlow, D. J. Birkett and D. N. Wade, The characterization of two specific drug binding sites on human serum albumin, *Mol. Pharmacol.*, 1975, **11**(6), 824–832.

35 J. Ghuman, P. A. Zunszain, I. Petitpas, A. A. Bhattacharya, M. Otagiri and S. Curry, Structural basis of the drug-binding specificity of human serum albumin, *J. Mol. Biol.*, 2005, **353**(1), 38–52.

36 M. F. Koehler, K. Zobel, M. H. Beresini, L. D. Caris, D. Combs and B. D. Paasch, *et al.*, Albumin affinity tags increase peptide half-life in vivo, *Bioorg. Med. Chem. Lett.*, 2002, **12**(20), 2883–2886.

37 K. Zobel, M. F. Koehler, M. H. Beresini, L. D. Caris and D. Combs, Phosphate ester serum albumin affinity tags greatly improve peptide half-life in vivo, *Bioorg. Med. Chem. Lett.*, 2003, **13**(9), 1513–1515.

38 H. Zhang, *Trisodium-[(2-(R)-[(4,4-diphenylcyclohexyl)phosphono-oxymethyl]-diethylenetriamin epentaacetato)(aquo)gadolinium(III)-Gadofosveset*, Molecular Imaging and Contrast Agent Database (MICAD), Bethesda (MD), 2004.

39 Y. Shechter, M. Mironchik, A. Saul, E. Gershonov, L. Precido-Patt and K. Sasson, *et al.*, New Technologies to Prolong Life-time of Peptide and Protein Drugs In vivo, *Int. J. Pept. Res. Ther.*, 2007, **13**(1–2), 12.

40 K. Sasson, Y. Marcus, V. Lev-Goldman, S. Rubinraut, M. Fridkin and Y. Shechter, Engineering prolonged-acting

prodrugs employing an albumin-binding probe that undergoes slow hydrolysis at physiological conditions, *J. Controlled Release*, 2010, **142**(2), 214–220.

41 J. Han, L. Sun, Y. Chu, Z. Li, D. Huang and X. Zhu, *et al.*, Design, synthesis, and biological activity of novel dicoumarol glucagon-like peptide 1 conjugates, *J. Med. Chem.*, 2013, **56**(24), 9955–9968.

42 O. Jacobson, D. O. Kiesewetter and X. Chen, Albumin-Binding Evans Blue Derivatives for Diagnostic Imaging and Production of Long-Acting Therapeutics, *Bioconjugate Chem.*, 2016, **27**(10), 2239–2247.

43 H. Chen, G. Wang, L. Lang, O. Jacobson, D. O. Kiesewetter and Y. Liu, *et al.*, Chemical Conjugation of Evans Blue Derivative: A Strategy to Develop Long-Acting Therapeutics through Albumin Binding, *Theranostics*, 2016, **6**(2), 243–253.

44 Y. Liu, G. Wang, H. Zhang, Y. Ma, L. Lang and O. Jacobson, *et al.*, Stable Evans Blue Derived Exendin-4 Peptide for Type 2 Diabetes Treatment, *Bioconjugate Chem.*, 2016, **27**(1), 54–58.

45 G. Zhu, G. M. Lynn, O. Jacobson, K. Chen, Y. Liu and H. Zhang, *et al.*, Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy, *Nat. Commun.*, 2017, **8**(1), 1954.

46 E. M. Bech, M. C. Martos-Maldonado, P. Wismann, K. K. Sorensen, S. B. van Witteloostuijn and M. B. Thygesen, *et al.*, Peptide Half-Life Extension: Divalent, Small-Molecule Albumin Interactions Direct the Systemic Properties of Glucagon-Like Peptide 1 (GLP-1) Analogues, *J. Med. Chem.*, 2017, **60**(17), 7434–7446.

47 I. Jonassen, S. Havelund, U. Ribel, A. Plum, M. Loftager and T. Hoeg-Jensen, *et al.*, Biochemical and physiological properties of a novel series of long-acting insulin analogs obtained by acylation with cholic acid derivatives, *Pharm. Res.*, 2006, **23**(1), 49–55.

48 C. E. Dumelin, S. Trussel, F. Buller, E. Trachsel, F. Bootz and Y. Zhang, *et al.*, A portable albumin binder from a DNA-encoded chemical library, *Angew. Chem., Int. Ed.*, 2008, **47**(17), 3196–3201.

49 S. S. Trüssel, J. Scheuermann and D. Neri, Half-Life Extension by Binding to Albumin through Small Molecules, in: *Therapeutic Proteins: Strategies to Modulate Their Plasma Half-Lives*, ed. R. Kontermann, Wiley-VCH Verlag GmbH & Co., 2012, ch. 15.

50 R. M. Franzini, T. Ekblad, N. Zhong, M. Wichert, W. Decurtins and A. Nauer, *et al.*, Identification of structure-activity relationships from screening a structurally compact DNA-encoded chemical library, *Angew. Chem., Int. Ed.*, 2015, **54**(13), 3927–3931.

51 R. M. Franzini, A. Nauer, J. Scheuermann and D. Neri, Interrogating target-specificity by parallel screening of a DNA-encoded chemical library against closely related proteins, *Chem. Commun.*, 2015, **51**(38), 8014–8016.

52 S. Trussel, C. Dumelin, K. Frey, A. Villa, F. Buller and D. Neri, New strategy for the extension of the serum half-life of antibody fragments, *Bioconjugate Chem.*, 2009, **20**(12), 2286–2292.

53 C. Muller, H. Struthers, C. Winiger, K. Zhernosekov and R. Schibli, DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177Lu-radionuclide tumor therapy in mice, *J. Nucl. Med.*, 2013, **54**(1), 124–131.

54 J. M. Kelly, A. Amor-Coarasa, A. Nikolopoulou, T. Wustemann, P. Barelli and D. Kim, *et al.*, Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer, *J. Nucl. Med.*, 2017, **58**(9), 1442–1449.

55 J. Kelly, A. Amor-Coarasa, S. Ponnala, A. Nikolopoulou, C. Williams Jr. and D. Schlyer, *et al.*, Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors, *Eur. J. Nucl. Med. Mol. Imaging*, 2018, **45**(11), 1841–1851.

56 J. M. Kelly, A. Amor-Coarasa, S. Ponnala, A. Nikolopoulou, C. Williams Jr. and S. G. DiMagno, *et al.*, Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window, *J. Nucl. Med.*, 2018, **60**(5), 656–663.

57 C. A. Umbricht, M. Benesova, R. Hasler, R. Schibli, N. P. van der Meulen and C. Muller, Design and Preclinical Evaluation of an Albumin-Binding PSMA Ligand for (64)Cu-Based PET Imaging, *Mol. Pharmaceutics*, 2018, **15**(12), 5556–5564.

58 M. S. Lowenthal, A. I. Mehta, K. Frogale, R. W. Bandle, R. P. Araujo and B. L. Hood, *et al.*, Analysis of albumin-associated peptides and proteins from ovarian cancer patients, *Clin. Chem.*, 2005, **51**(10), 1933–1945.

59 R. L. Gundry, Q. Fu, C. A. Jelinek, J. E. Van Eyk and R. J. Cotter, Investigation of an albumin-enriched fraction of human serum and its albuminome, *Proteomics: Clin. Appl.*, 2007, **1**(1), 73–88.

60 M. S. Dennis, M. Zhang, Y. G. Meng, M. Kadkhodayan, D. Kirchhofer and D. Combs, *et al.*, Albumin binding as a general strategy for improving the pharmacokinetics of proteins, *J. Biol. Chem.*, 2002, **277**(38), 35035–35043.

61 A. K. Sato, D. J. Sexton, L. A. Morganelli, E. H. Cohen, Q. L. Wu and G. P. Conley, *et al.*, Development of mammalian serum albumin affinity purification media by peptide phage display, *Biotechnol. Prog.*, 2002, **18**(2), 182–192.

62 A. Zorzi, S. J. Middendorp, J. Wilbs, K. Deyle and C. Heinis, Acylated heptapeptide binds albumin with high affinity and application as tag furnishes long-acting peptides, *Nat. Commun.*, 2017, **8**, 16092.

63 Y. Li, R. De Luca, S. Cazzamalli, F. Pretto, D. Bajic and J. Scheuermann, *et al.*, Versatile protein recognition by the encoded display of multiple chemical elements on a constant macrocyclic scaffold, *Nat. Chem.*, 2018, **10**(4), 441–448.

64 L. H. Pollaro, C. Strategies to prolong the plasma residence time of peptide drugs, *Med. Chem. Commun.*, 2010, **1**, 5.

65 H. A. P. Revets and C. Boutton, *Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same*, WO2011095545, 2011.

66 A. Nguyen, A. E. Reyes 2nd, M. Zhang, P. McDonald, W. L. Wong and L. A. Damico, *et al.*, The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin, *Protein Eng., Des. Sel.*, 2006, **19**(7), 291–297.

67 A. Angelini, J. Morales-Sanfrutos, P. Diderich, S. Chen and C. Heinis, Bicyclization and tethering to albumin yields long-acting peptide antagonists, *J. Med. Chem.*, 2012, **55**(22), 10187–10197.

68 L. Pollaro, S. Raghunathan, J. Morales-Sanfrutos, A. Angelini, S. Kontos and C. Heinis, Bicyclic peptides conjugated to an albumin-binding tag diffuse efficiently into solid tumors, *Mol. Cancer Ther.*, 2015, **14**(1), 151–161.

69 M. S. Dennis, H. Jin, D. Dugger, R. Yang, L. McFarland and A. Ogasawara, *et al.*, Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent, *Cancer Res.*, 2007, **67**(1), 254–261.

70 J. F. Langenheim and W. Y. Chen, Improving the pharmacokinetics/pharmacodynamics of prolactin, GH, and their antagonists by fusion to a synthetic albumin-binding peptide, *J. Endocrinol.*, 2009, **203**(3), 375–387.

71 J. Nilvebrant and S. Hober, The albumin-binding domain as a scaffold for protein engineering, *Comput. Struct. Biotechnol. J.*, 2013, **6**, e201303009.

72 A. Jonsson, J. Dogan, N. Herne, L. Abrahmsen and P. A. Nygren, Engineering of a femtomolar affinity binding protein to human serum albumin, *Protein Eng., Des. Sel.*, 2008, **21**(8), 515–527.

73 S. C. Makrides, P. A. Nygren, B. Andrews, P. J. Ford, K. S. Evans and E. G. Hayman, *et al.*, Extended in vivo half-life of human soluble complement receptor type 1 fused to a serum albumin-binding receptor, *J. Pharmacol. Exp. Ther.*, 1996, **277**(1), 534–542.

74 R. Li, H. Yang, D. Jia, Q. Nie, H. Cai and Q. Fan, *et al.*, Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL, *J. Controlled Release*, 2016, **228**, 96–106.

75 R. Stork, D. Muller and R. E. Kontermann, A novel trifunctional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G, *Protein Eng., Des. Sel.*, 2007, **20**(11), 569–576.

76 J. Hopp, N. Hornig, K. A. Zettlitz, A. Schwarz, N. Fuss and D. Muller, *et al.*, The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein, *Protein Eng., Des. Sel.*, 2010, **23**(11), 827–834.

77 Y. Masuda, S. Yamaguchi, C. Suzuki, T. Aburatani, Y. Nagano and R. Miyauchi, *et al.*, Generation and Characterization of a Novel Small Biologic Alternative to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Antibodies, DS-9001a, Albumin Binding Domain-Fused Anticalin Protein, *J. Pharmacol. Exp. Ther.*, 2018, **365**(2), 368–378.

78 R. Guo, W. Guo, L. Cao, H. Liu, J. Liu and H. Xu, *et al.*, Fusion of an albumin-binding domain extends the half-life of immunotoxins, *Int. J. Pharm.*, 2016, **511**(1), 538–549.

79 J. Wei, T. K. Bera, X. F. Liu, Q. Zhou, M. Onda and M. Ho, *et al.*, Recombinant immunotoxins with albumin-binding

1080 | *Med. Chem. Commun.*, 2019, **10**, 1068–1081

This journal is © The Royal Society of Chemistry 2019

domains have long half-lives and high antitumor activity, *Proc. Natl. Acad. Sci. U. S. A.*, 2018, **115**(15), E3501–E3508.

80   J. T. Andersen, R. Pehrson, V. Tolmachev, M. B. Daba, L. Abrahmsen and C. Ekblad, Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain, *J. Biol. Chem.*, 2011, **286**(7), 5234–5241.

81   A. Orlova, A. Jonsson, D. Rosik, H. Lundqvist, M. Lindborg and L. Abrahmsen, *et al.*, Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein, *J. Nucl. Med.*, 2013, **54**(6), 961–968.

82   F. Y. Frejd and K. T. Kim, Affibody molecules as engineered protein drugs, *Exp. Mol. Med.*, 2017, **49**(3), e306.

83   O. E. Levy, C. M. Jodka, S. S. Ren, L. Mamedova, A. Sharma and M. Samant, *et al.*, Novel exenatide analogs with peptidic albumin binding domains: potent anti-diabetic agents with extended duration of action, *PLoS One*, 2014, **9**(2), e87704.

84   S. A. Jacobs, A. C. Gibbs, M. Conk, F. Yi, D. Maguire and C. Kane, *et al.*, Fusion to a highly stable consensus albumin binding domain allows for tunable pharmacokinetics, *Protein Eng., Des. Sel.*, 2015, **28**(10), 385–393.

85   Y. G. Gao, S. Y. Su, H. Robinson, S. Padmanabhan, L. Lim and B. S. McCrary, *et al.*, The crystal structure of the hyperthermophile chromosomal protein Sso7d bound to DNA, *Nat. Struct. Biol.*, 1998, **5**(9), 782–786.

86   M. W. Traxlmayr, J. D. Kiefer, R. R. Srinivas, E. Lobner, A. W. Tisdale and N. K. Mehta, *et al.*, Strong Enrichment of Aromatic Residues in Binding Sites from a Charge-neutralized Hyperthermostable Sso7d Scaffold Library, *J. Biol. Chem.*, 2016, **291**(43), 22496–22508.

87   N. Zhao, M. A. Schmitt and J. D. Fisk, Phage display selection of tight specific binding variants from a hyperthermostable Sso7d scaffold protein library, *Rev. Geophys.*, 2016, **283**(7), 1351–1367.

88   A. Pluckthun, Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy, *Annu. Rev. Pharmacol. Toxicol.*, 2015, **55**, 489–511.

89   D. Steiner, F. W. Merz, I. Sonderegger, M. Gulotti-Georgieva, D. Villemagne and D. J. Phillips, *et al.*, Half-life extension using serum albumin-binding DARPin(R) domains, *Protein Eng., Des. Sel.*, 2017, **30**(9), 583–591.

90   G. Winter, A. D. Griffiths, R. E. Hawkins and H. R. Hoogenboom, Making antibodies by phage display technology, *Annu. Rev. Immunol.*, 1994, **12**, 433–455.

91   L. J. Holt, A. Basran, K. Jones, J. Chorlton, L. S. Jespers and N. D. Brewis, *et al.*, Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs, *Protein Eng., Des. Sel.*, 2008, **21**(5), 283–288.

92   A. Walker, G. Dunlevy, D. Rycroft, P. Topley, L. J. Holt and T. Herbert, *et al.*, Anti-serum albumin domain antibodies in the development of highly potent, efficacious and long-

acting interferon, *Protein Eng., Des. Sel.*, 2010, **23**(4), 271–278.

93   L. J. Goodall, M. Ovecka, D. Rycroft, S. L. Friel, A. Sanderson and P. Mistry, *et al.*, Pharmacokinetic and Pharmacodynamic Characterisation of an Anti-Mouse TNF Receptor 1 Domain Antibody Formatted for In Vivo Half-Life Extension, *PLoS One*, 2015, **10**(9), e0137065.

94   R. L. O'Connor-Semmes, J. Lin, R. J. Hodge, S. Andrews, J. Chism and A. Choudhury, *et al.*, GSK2374697, a novel albumin-binding domain antibody (AlbudAb), extends systemic exposure of exendin-4: first study in humans–PK/PD and safety, *Clin. Pharmacol. Ther.*, 2014, **96**(6), 704–712.

95   C. Read, P. Yang, R. E. Kuc, D. Nyimanu, T. L. Williams and R. C. Glen, *et al.*, Apelin peptides linked to anti-serum albumin domain antibodies retain affinity in vitro and are efficacious receptor agonists in vivo, *Basic Clin. Pharmacol. Toxicol.*, 2019, 1–8.

96   R. Adams, L. Griffin, J. E. Compson, M. Jairaj, T. Baker and T. Ceska, *et al.*, Extending the half-life of a fab fragment through generation of a humanized anti-human serum albumin Fv domain: An investigation into the correlation between affinity and serum half-life, *mAbs*, 2016, **8**(7), 1336–1346.

97   E. Dave, R. Adams, O. Zaccheo, B. Carrington, J. E. Compson and S. Dugdale, *et al.*, Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding, *mAbs*, 2016, **8**(7), 1319–1335.

98   S. Steeland, R. E. Vandenbroucke and C. Libert, Nanobodies as therapeutics: big opportunities for small antibodies, *Drug Discovery Today*, 2016, **21**(7), 1076–1113.

99   K. Coppieters, T. Dreier, K. Silence, H. de Haard, M. Lauwereys and P. Casteels, *et al.*, Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis, *Arthritis Rheum.*, 2006, **54**(6), 1856–1866.

100 M. Van Roy, C. Ververken, E. Beirnaert, S. Hoefman, J. Kolkman and M. Vierboom, *et al.*, The preclinical pharmacology of the high affinity anti-IL-6R Nanobody(R) ALX-0061 supports its clinical development in rheumatoid arthritis, *Arthritis Res. Ther.*, 2015, **17**, 135.

101 C. McMahon, A. S. Baier, R. Pascolutti, M. Wegrecki, S. Zheng and J. X. Ong, *et al.*, Yeast surface display platform for rapid discovery of conformationally selective nanobodies, *Nat. Struct. Mol. Biol.*, 2018, **25**(3), 289–296.

102 M. R. Muller, K. Saunders, C. Grace, M. Jin, N. Piche-Nicholas and J. Steven, *et al.*, Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain, *mAbs*, 2012, **4**(6), 673–685.

103 S. Zielonka, M. Empting, J. Grzeschik, D. Konning, C. J. Barelle and H. Kolmar, Structural insights and biomedical potential of IgNAR scaffolds from sharks, *mAbs*, 2015, **7**(1), 15–25.

This journal is © The Royal Society of Chemistry 2019

Med. Chem. Commun., 2019, **10**, 1068–1081 | 1081